Cantor Fitzgerald downgraded Intra-Cellular (ITCI) to Neutral from Overweight with a price target of $132, down from $135, after Johnson & Johnson said will acquire all outstanding shares of Intra-Cellular for a payment of $132 per share in cash.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ITCI:
- Intra-Cellular downgraded to Hold from Buy at Needham
- Intra-Cellular downgraded to Equal Weight from Overweight at Morgan Stanley
- Morning Movers: Intra-Cellular surges following deal to be bought by J&J
- Johnson & Johnson to Acquire Intra-Cellular Therapies
- M&A News: Intra-Cellular Stock Rallies 36% on News of $14.6B Acquisition by Johnson & Johnson